Tenpoint Therapeutics Strengthens Leadership Team with Appointment of Melissa Epperly as CFO

Tenpoint Therapeutics, a clinical-stage biotechnology company dedicated to innovating treatments for vision rejuvenation in the aging eye, has announced the appointment of Melissa Epperly as its Chief Financial Officer. This strategic hire comes at a pivotal time as the company prepares for the potential U.S. market introduction of BRIMOCHOLPF, its leading candidate for treating presbyopia, a condition affecting nearly two billion people worldwide.

Epperly's extensive experience in financial leadership within the biopharmaceutical sector is expected to play a critical role in Tenpoint's growth trajectory. With a career spanning over two decades, including significant roles at Zentalis Pharmaceuticals, PsiOxus Therapeutics, and R-Pharm US, Epperly has demonstrated her capability in navigating the complex financial landscapes of both public and private companies. Her expertise in capital markets and operational finance is anticipated to be invaluable as Tenpoint transitions into a commercial-stage entity.

The appointment underscores Tenpoint's commitment to advancing its pipeline of innovative treatments for ophthalmic conditions, including presbyopia, cataracts, and geographic atrophy. With BRIMOCHOLPF having completed Phase 3 trials and an NDA submission to the U.S. FDA, the company is on the cusp of a significant milestone. Epperly's leadership is expected to enhance Tenpoint's financial strategy and operational efficiency, ensuring the company is well-positioned for future growth and the successful commercialization of its treatments.

Henric Bjarke, CEO of Tenpoint Therapeutics, highlighted the importance of Epperly's appointment, noting her proven track record in financial leadership and capital markets. Epperly herself expressed enthusiasm about joining Tenpoint, citing the company's groundbreaking science and potential for global impact. Her role will be crucial in steering the company through its next phase of development, including the anticipated launch of BRIMOCHOLPF and the pursuit of lasting growth in the biotech industry.

This development is significant not only for Tenpoint Therapeutics but also for the broader biopharmaceutical industry and patients worldwide. The successful commercialization of BRIMOCHOLPF could offer a novel treatment option for presbyopia, addressing a substantial unmet medical need and improving the quality of life for millions. Epperly's appointment signals Tenpoint's readiness to navigate the challenges of bringing innovative therapies to market, marking an important step forward in the company's mission to rejuvenate vision in the aging eye.